Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169673 | 0.92 | UGCG (0.35) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2169212 | 0.92 | HPGD (0.33) | TSHRMEN1KMT2ALMNAHPGD | |
| SCHEMBL2177347 | 0.92 | TNIK (0.33) | HTR2ACHRM1MCHR1 | |
| SCHEMBL2181012 | 0.92 | KMT2A (0.37) | HRH3MEN1KMT2ALMNAMAPT | |
| SCHEMBL2169009 | 0.90 | UGCG (0.38) | HRH3TSHRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2167612 | 0.87 | GAA (0.36) | HTR2ACHRM1MCHR1TSHRMAPT | |
| SCHEMBL2168333 | 0.84 | UGCG (0.39) | MCHR1HRH3LMNAALDH1A1GAA | |
| SCHEMBL2181889 | 0.83 | KDM4E (0.40) | HTR2ACHRM1MCHR1HRH3MEN1 | |
| SCHEMBL2166991 | 0.82 | UGCG (0.40) | MEN1KMT2ALMNAMAPTEPHX1 | |
| SCHEMBL2167637 | 0.82 | MEN1 (0.38) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2016-11-24 | — | — | US | disclosed |
| US-9481671-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2594564-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9272996-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225393-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2015-08-13 | — | — | US | disclosed |
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2594562-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8389517-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HTR2A 4285/4885CHRM1 4735/4885MCHR1 4006/4885 |
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | SGMS1, SGMS2, CERS2 | HTR2A 4285/4885CHRM1 4735/4885MCHR1 4006/4885 |
| US-20150225393-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | HTR2A 3243/4885CHRM1 4852/4885MCHR1 4110/4885 |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | HTR2A 4048/4885CHRM1 4873/4885MCHR1 4574/4885 |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | HTR2A 3243/4885CHRM1 4852/4885MCHR1 4110/4885 |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | HTR2A 4048/4885CHRM1 4873/4885MCHR1 4574/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HTR2A 4285/4885CHRM1 4735/4885MCHR1 4006/4885 |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GBA1, UGCG, GBA2 | HTR2A 4468/4885CHRM1 4838/4885MCHR1 3337/4885 |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GBA1, UGCG, GBA2 | HTR2A 4468/4885CHRM1 4838/4885MCHR1 3337/4885 |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | HTR2A 4048/4885CHRM1 4873/4885MCHR1 4574/4885 |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HTR2A 4285/4885CHRM1 4735/4885MCHR1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.